Compounds > cp-166,572
Page last updated: 2024-11-07

cp-166,572

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID132302
CHEMBL ID90488
SCHEMBL ID7047595
MeSH IDM0276593

Synonyms (28)

Synonym
cp-166572
CHEMBL90488 ,
140687-51-0
zi4emq9wye ,
cp-166,572
4-(4-(n,n-dimethyl-sulfamoyl)piperazino)-2-hydroxymethylpyrimidine
unii-zi4emq9wye
sdi-2 cpd
cp166,572
cp 166572
2-hydroxymethyl-4-(4-(n,n-dimethylaminosulfonyl)-1-piperazino)pyrimidine
way-135706
4-[2-(hydroxymethyl)pyrimidin-4-yl]-n,n-dimethylpiperazine-1-sulfonamide
DB04478
cp-166572, 2-hydroxymethyl-4-(4-n,n-dimethylaminosulfonyl-1-piperazino)-pyrimidine
way 135706
4-(2-hydroxymethyl-pyrimidin-4-yl)-piperazine-1-sulfonic acid dimethylamide
bdbm50102723
sdi-158
SCHEMBL7047595
XDTHNROWHAAVPJ-UHFFFAOYSA-N
4-[4-(n,n-dimethylsulfamoyl)piperazino]-2-hydroxymethylpyrimidine
DTXSID20161460
cp-166572; 2-hydroxymethyl-4-(4-n,n-dimethylaminosulfonyl-1-piperazino)-pyrimidine
1-piperazinesulfonamide, 4-(2-(hydroxymethyl)-4-pyrimidinyl)-n,n-dimethyl-
4-(2-(hydroxymethyl)pyrimidin-4-yl)-n,n-dimethylpiperazine-1-sulfonamide
Q27095253
PD006654
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sorbitol dehydrogenaseHomo sapiens (human)IC50 (µMol)0.49530.24000.49531.0000AID200761; AID203723; AID226558
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (7)

Processvia Protein(s)Taxonomy
glucose metabolic processSorbitol dehydrogenaseHomo sapiens (human)
sorbitol catabolic processSorbitol dehydrogenaseHomo sapiens (human)
glucuronate catabolic process to xylulose 5-phosphateSorbitol dehydrogenaseHomo sapiens (human)
flagellated sperm motilitySorbitol dehydrogenaseHomo sapiens (human)
fructose biosynthetic processSorbitol dehydrogenaseHomo sapiens (human)
L-xylitol catabolic processSorbitol dehydrogenaseHomo sapiens (human)
L-xylitol metabolic processSorbitol dehydrogenaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
(R,R)-butanediol dehydrogenase activitySorbitol dehydrogenaseHomo sapiens (human)
L-iditol 2-dehydrogenase activitySorbitol dehydrogenaseHomo sapiens (human)
zinc ion bindingSorbitol dehydrogenaseHomo sapiens (human)
carbohydrate bindingSorbitol dehydrogenaseHomo sapiens (human)
identical protein bindingSorbitol dehydrogenaseHomo sapiens (human)
D-xylulose reductase activitySorbitol dehydrogenaseHomo sapiens (human)
D-sorbitol dehydrogenase (acceptor) activitySorbitol dehydrogenaseHomo sapiens (human)
ribitol 2-dehydrogenase activitySorbitol dehydrogenaseHomo sapiens (human)
NAD bindingSorbitol dehydrogenaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
extracellular spaceSorbitol dehydrogenaseHomo sapiens (human)
cytosolSorbitol dehydrogenaseHomo sapiens (human)
membraneSorbitol dehydrogenaseHomo sapiens (human)
motile ciliumSorbitol dehydrogenaseHomo sapiens (human)
mitochondrial membraneSorbitol dehydrogenaseHomo sapiens (human)
extracellular exosomeSorbitol dehydrogenaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID177517In vivo inhibition of diabetic rat sciatic nerve fructose accumulation2001Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17
Sorbitol dehydrogenase inhibitors (SDIs): a new potent, enantiomeric SDI, 4-[2-1R-hydroxy-ethyl)-pyrimidin-4-yl]piperazine-1-sulfonic acid dimethylamide.
AID200761In vitro inhibitory activity against human SDH2001Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17
Sorbitol dehydrogenase inhibitors (SDIs): a new potent, enantiomeric SDI, 4-[2-1R-hydroxy-ethyl)-pyrimidin-4-yl]piperazine-1-sulfonic acid dimethylamide.
AID226558Concentration required for inhibitory activity against human sorbitol dehydrogenase (SDH)2001Bioorganic & medicinal chemistry letters, Dec-17, Volume: 11, Issue:24
Modelling studies of the active site of human sorbitol dehydrogenase: an approach to structure-based inhibitor design of the enzyme.
AID203723Concentration required for 50% in vitro inhibition of recombinant human sorbitol dehydrogenase (h-SDH)2002Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
Orally-effective, long-acting sorbitol dehydrogenase inhibitors: synthesis, structure-activity relationships, and in vivo evaluations of novel heterocycle-substituted piperazino-pyrimidines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (50.00)18.2507
2000's5 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.89 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
inositol
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.. inositol : Any cyclohexane-1,2,3,4,5,6-hexol.. 1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.. muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.		1.9910cyclitol;
hexol
zopolrestat
zopolrestat: structure given in first source		2.420
ponalrestat
[no description available]		1.9910phthalazines
sorbitol
D-glucitol : The D-enantiomer of glucitol (also known as D-sorbitol).		2.9140glucitolcathartic;
Escherichia coli metabolite;
food humectant;
human metabolite;
laxative;
metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite;
sweetening agent
galactose
galactopyranose : The pyranose form of galactose.		1.9910D-galactose;
galactopyranose		Escherichia coli metabolite;
mouse metabolite
mannitol
[no description available]		1.9910mannitolallergen;
antiglaucoma drug;
compatible osmolytes;
Escherichia coli metabolite;
food anticaking agent;
food bulking agent;
food humectant;
food stabiliser;
food thickening agent;
hapten;
metabolite;
osmotic diuretic;
sweetening agent
thiazoles
[no description available]		2.4201,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
hydantoins
Hydantoins: Compounds based on imidazolidine dione. Some derivatives are ANTICONVULSANTS.. imidazolidine-2,4-dione : An imidazolidinone with oxo groups at position 2 and 4.		1.9910imidazolidine-2,4-dione
imirestat
imirestat: structure given in first source		1.9910
sorbinil
sorbinil: aldose reductase inhibitor. sorbinil : An azaspiro compound having a monofluoro-substituted chromane skeleton spiro-linked to an imidazolidinedione ring.		1.9910azaspiro compound;
chromanes;
imidazolidinone;
organofluorine compound;
oxaspiro compound		antioxidant;
EC 1.1.1.21 (aldehyde reductase) inhibitor
arachidonic acid
icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.		1.9910icosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid		Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite
imidazolidines
[no description available]		1.9910azacycloalkane;
imidazolidines;
saturated organic heteromonocyclic parent
D-fructopyranose
[no description available]		2.6830cyclic hemiketal;
D-fructose;
fructopyranose		sweetening agent
nad
NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety.		1.9910organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Alloxan Diabetes
[description not available]		03.150
Chronic Illness
[description not available]		02.0110
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		02.0110
Cataract, Membranous
[description not available]		02.4120
Cataract
Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed)		02.4120
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		01.9910
Neurofibroma
A moderately firm, benign, encapsulated tumor resulting from proliferation of SCHWANN CELLS and FIBROBLASTS that includes portions of nerve fibers. The tumors usually develop along peripheral or cranial nerves and are a central feature of NEUROFIBROMATOSIS 1, where they may occur intracranially or involve spinal roots. Pathologic features include fusiform enlargement of the involved nerve. Microscopic examination reveals a disorganized and loose cellular pattern with elongated nuclei intermixed with fibrous strands. (From Adams et al., Principles of Neurology, 6th ed, p1016)		01.9910
Adult Neuroaxonal Dystrophy
[description not available]		01.9910
ANS (Autonomic Nervous System) Diseases
[description not available]		01.9910
Asymmetric Diabetic Proximal Motor Neuropathy
[description not available]		01.9910
Diabetic Neuropathies
Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)		01.9910